Armata Pharmaceuticals (ARMP) AI Stock Analysis

• Market Cap: $257.23M
• Dividend Yield: N/A
• Average Volume (3M): 477.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 84.67%
• EPS Growth: 61.76%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 36,229,843
• 10 Day Avg. Volume: 1,414,916
• 30 Day Avg. Volume: 477,077
• PEG Ratio: 0.05
• Price to Book (P/B): -1.39
• Price to Sales (P/S): 12.93
• P/FCF Ratio: -1.70
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 30.34
• Enterprise Value/Gross Profit: 38.36
• Enterprise Value/Ebitda: -19.55
• 1Y Price Target: $9.00
• Price Target Upside: 158.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: $3.50 ▲(0.57% Upside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by negative revenue growth and persistent losses. While technical analysis indicates strong upward momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Innovative Therapy Development

The positive results from the Phase 2a diSArm study validate Armata's phage therapy, potentially setting a new standard for treating severe bacterial infections, which could lead to significant market opportunities and partnerships.

Strategic Partnerships

Potential partnerships with larger pharmaceutical companies can provide Armata with milestone payments and royalties, enhancing revenue streams and supporting R&D efforts, crucial for long-term growth and sustainability.

Proprietary Technology

Armata's proprietary bacteriophage technology positions it uniquely in the biotechnology sector, offering a competitive edge in developing treatments for antibiotic-resistant infections, a growing global health concern.

Negative Factors

Financial Distress

Persistent financial losses and negative revenue growth highlight significant financial distress, potentially limiting the company's ability to fund R&D and operational activities, impacting long-term viability.

Negative Cash Flow

Negative cash flow indicates inefficient cash management and reliance on external financing, which may constrain Armata's operational flexibility and ability to invest in future growth initiatives.

Weak Balance Sheet

A weak balance sheet with negative equity suggests insolvency risks, limiting Armata's financial stability and ability to withstand economic downturns or invest in strategic opportunities.

Armata Pharmaceuticals Business Overview & Revenue Model

Company Description

Armata Pharmaceuticals (ARMP) is a biotechnology company focused on developing innovative therapies for the treatment of antibiotic-resistant infections. The company operates primarily in the pharmaceutical sector, leveraging its proprietary bacteriophage technology to create targeted therapies that address the growing challenge of multi-drug resistant pathogens. Armata's core products include its lead therapeutic candidates aimed at treating serious bacterial infections, potentially offering alternatives to traditional antibiotics.

How the Company Makes Money

Armata Pharmaceuticals generates revenue primarily through the development and commercialization of its bacteriophage-based therapies. The company may receive funding from government grants and contracts, particularly for research and development initiatives aimed at addressing public health challenges. Additionally, Armata may enter into partnerships and collaborations with larger pharmaceutical companies, which can provide milestone payments and royalties on sales of products developed through these partnerships. The company could also explore licensing agreements that enable it to monetize its intellectual property and technology platforms. These diverse revenue streams are critical for supporting its ongoing clinical trials and operational expenses.

Armata Pharmaceuticals Financial Statement Overview

Summary

Armata Pharmaceuticals is facing serious financial challenges, with negative revenue growth, persistent losses, and a weak balance sheet with negative equity. The cash flow situation is strained, heavily reliant on financing. The company must address these financial deficiencies to improve its financial health and sustainability.

Income Statement

Armata Pharmaceuticals shows a significant decline in revenue with no revenue reported in the most recent year from $4.5 million the previous year. The company has been consistently operating at a loss, with increasing negative EBIT and EBITDA margins. The net profit margin is also negative due to substantial net losses over the years, indicating financial distress.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning as liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, but high total liabilities relative to assets suggest a heavily leveraged position. The equity ratio is negative, indicating insolvency risks.

Cash Flow

Free cash flow remains negative, but there is a minor improvement in free cash flow growth due to reduced negative cash flow. The operating cash flow is significantly negative and larger than net income, suggesting inefficient cash management. The company relies on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.87M	5.17M	4.53M	5.51M	4.47M	823.00K
Gross Profit	5.43M	3.85M	-29.24M	4.62M	-15.54M	-13.62M
EBITDA	-10.66M	-6.85M	-39.92M	-36.05M	-22.65M	-20.44M
Net Income	-25.71M	-18.92M	-69.05M	-36.92M	-23.16M	-22.18M
Balance Sheet
Total Assets	80.79M	86.44M	98.36M	95.83M	69.77M	39.52M
Cash, Cash Equivalents and Short-Term Investments	4.33M	9.29M	13.52M	14.85M	10.29M	9.65M
Total Debt	110.51M	126.52M	120.37M	48.81M	37.99M	13.15M
Total Liabilities	150.29M	134.46M	130.43M	59.75M	44.37M	20.66M
Stockholders Equity	-69.50M	-48.02M	-32.06M	36.08M	25.40M	18.86M
Cash Flow
Free Cash Flow	-32.09M	-39.43M	-55.57M	-34.69M	-24.88M	-19.09M
Operating Cash Flow	-31.58M	-37.55M	-47.42M	-32.48M	-23.57M	-18.27M
Investing Cash Flow	-511.00K	-1.88M	-8.13M	-2.21M	-1.30M	-824.00K
Financing Cash Flow	9.93M	34.96M	53.99M	44.02M	25.52M	23.21M

Armata Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Positive. The current price of 3.48 is below the 20-day moving average (MA) of 3.75, above the 50-day MA of 3.18, and above the 200-day MA of 2.23, indicating a bullish trend. The MACD of 0.75 indicates Negative momentum. The RSI at 73.99 is Negative, neither overbought nor oversold. The STOCH value of 27.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARMP.

Armata Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARMP	52 Neutral	$257.23M	―	―	―	84.67%	61.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORMP	47 Neutral	$97.18M	―	-14.57%	―	―	-217.26%
VERU	45 Neutral	$54.53M	―	-96.35%	―	-52.76%	43.40%
ELUT	45 Neutral	$37.76M	―	―	―	-5.22%	82.06%
ADAG	40 Underperform	$82.95M	―	-63.41%	―	-87.59%	11.53%
INKT	38 Underperform	$63.32M	―	―	―	―	41.90%

Armata Pharmaceuticals Corporate Events

Armata Pharmaceuticals Reports Positive Phase 2a Study Results

On October 22, 2025, Armata Pharmaceuticals announced positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage cocktail for treating complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025. The study demonstrated higher cure rates and no relapse in patients treated with AP-SA02 compared to placebo, supporting the advancement to a Phase 3 trial. These findings suggest AP-SA02 could become a new standard of care for this severe infection, with implications for reducing hospital stays and improving patient outcomes.

The most recent analyst rating on (ARMP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Armata Pharmaceuticals Highlights Phage Therapy Progress

On September 10, 2025, Armata Pharmaceuticals‘ CEO, Dr. Deborah Birx, presented at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation highlighted the company’s progress and strategic plans in developing phage-based therapies, emphasizing their potential to address the global threat of antibiotic resistance. Armata is focused on conducting definitive pivotal trials to establish the efficacy and safety of phage therapy as an alternative or complement to standard antibiotics, aiming to position itself as a leader in this innovative field.

The most recent analyst rating on (ARMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Armata Pharmaceuticals Secures $15M Loan for Development

On August 11, 2025, Armata Pharmaceuticals entered into a secured credit agreement with Innoviva Strategic Opportunities LLC for a $15 million loan maturing in 2029. The funding will support the development of Armata’s lead therapeutic candidate, AP-SA02, which showed positive results in a Phase 1b/2a trial for treating complicated Staphylococcus aureus bacteremia. The trial met all primary endpoints, demonstrating improved clinical outcomes without serious adverse events. Armata plans to discuss a Phase 3 trial design with the FDA later this year, aiming to change the standard of care for this serious infection. Additionally, Armata received $4.65 million in non-dilutive funding from the U.S. Department of Defense to support its ongoing research efforts.

The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.